**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Caroline Ospelt
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © European Alliance of Associations for Rheumatology, *EULAR* 2023. Published by BMJ. All rights reserved.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Editorial

1503 Lessons from negative phase 3 trials in rheumatoid arthritis anno 2023
R Westhovens, P Verschueren

1506 Time to treat the climate and nature crisis as one indivisible global health emergency
 *Chris Zielinski, on behalf of the authorship group*

Viewpoint

1508 Potential for biosimilars in rheumatology in Africa
M H Abu-Zaid, A Adebajo, Y El Miedany

Review

1511 Contributions of joint damage-related events to gout pathogenesis: new insights from laboratory research
H Xu, H Qin, Y Hua, N Dalbeth

Rheumatoid arthritis

1516 Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contrASt 1 and contrASt 2)
R M Fleischmann, D van der Heijde, V Strand, T Atsumi, I B McInnes, T Takeuchi, P C Taylor, M Bracher, D Brooks, J Davies, C Goode, A Gupta, S Mukherjee, C O'Shea, D Saurigny, L A Schifano, C Shelton, J E Smith, M Wang, R Wang, S Watts, M E Weinblatt

1527 Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contrASt 3)
P C Taylor, M E Weinblatt, I B McInnes, T Atsumi, V Strand, T Takeuchi, M Bracher, D Brooks, J Davies, C Goode, A Gupta, S Mukherjee, C O'Shea, D Saurigny, L A Schifano, C Shelton, J E Smith, M Wang, R Wang, S Watts, R M Fleischmann

Early arthritis


1538 Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis
 *C Triaille, G Tilman, T Sokolova, A Lloriet, J Marchandise, S De Montjoye, A Nzeusseu-Toukap, L Méric de Bellefon, C Bouzine, C Galant, P Durez, B R Lauwerys, N Limaye*

1547 Directed differentiation of human pluripotent stem cells into articular cartilage reveals effects caused by absence of *WISP3*, the gene responsible for progressive pseudorheumatoid arthropathy of childhood
C Li, M Alemany-Ribes, R M Rafiqery, U Nwoko, M L Warman, A M Craft

Spondyloarthritis

1558 HLA-B27, axial spondyloarthritis and survival
 *Z Li, M K Khan, S M van der Linden, B Winkens, P M Villiger, H Baumberger, H van Zandwijk, M A Khan, M A Brown*

Systemic sclerosis

1568 Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups
 *K E N Clarke, S Xu, M Attah, V H Ong, C D Buckley, C P Denton*

Vasculitis

1580 Benralizumab for eosinophilic granulomatosis with polyangiitis
A Cottu, M Groh, C Desaintjean, S Marchand-Adam, L Guillevin, X Puechal, S Beaumesnil, E Lazaro, M Samson, C Taille, C-A Durel, E Diot, S Nicolas, L Guillemainault, M Ebbo, P Cathebras, C Dupin, H Yildiz, N Belfeki, G Pugnet, P Chauvin, S Jouneau, F Lifermann, J-P Martellosio, V Cottin, B Terrier, For the French Vasculitis Study Group

1587 Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study
B Molina, R Padoan, M L Urban, P Novikov, M Caminati, C Taillé, A Néel, L Bouillet, P Fraticelli, N Schleinitz, C Christides, L Moi, B Godeau, A Knight, J W Schroeder, S Marchand-Adam, H Gil, V Cottin, C-A Durel, E Gelain, B Lerais, M Ruivard, M Groh, M Samson, L Moroni, J Thiel, A Kernder, J W Cohen Tervaert, G Costanzo, M Folci, S Rizzello, P Cohen, G Emmi, B Terrier

MORE CONTENTS ►

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme. See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008
JM00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



recycle

When you have finished with this please recycle it

Autoinflammatory disorders

- 1594** Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about *UBA1* mosaicism



J M Mascaro, I Rodriguez-Pinto, G Poza, A Mensa-Vilaro, J Fernandez-Martin, L Caminal-Montero, G Espinosa, J Hernández-Rodríguez, M Díaz, J Rita-Marques, R Sanmarti, S Castañeda, D Colunga, R Coto-Hernández, P Fanlo, J I Elejalde, S Bujan, I Figueras, F M Marco, M Andrés, S Suárez, A Gonzalez-García, X Fustà-Novell, C García-Belando, A Granados, M T Fernandez-Figueras, N Quilis, M Orriols-Caba, R Gómez de la Torre, M C Cid, G Espigol-Frigolé, A Alvarez-Abella, E Labrador, M Rozman, M Lopez-Guerra, P Castillo, J R Alamo-Moreno, E Gonzalez-Roca, S Plaza, V Fabregat, R Lara, E F Vicente-Rabáneda, S Tejedor-Vaquero, G Magri, N Bonet, M Solís-Moruno, A Cerutti, O Fornas, F Casals, J Yagüe, J I Aróstegui

Osteoarthritis

- 1606** Evaluating the causal effect of circulating proteome on the risk of osteoarthritis-related traits

Y Zhang, J Xie, S Wen, P Cao, W Xiao, J Zhu, S Li, Z Wang, H Cen, Z Zhu, C Ding, G Ruan

Crystal arthropathies

- 1618** Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink



E Roddy, R Bajpai, H Forrester, R J Partington, C D Mallen, L E Clarkson, N Padmanabhan, R Whittle, S Muller

- 1626** Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial

L Stamp, A Horne, B Mihov, J Drake, J Haslett, P T Chapman, C Frampton, N Dalbeth

Images in rheumatology

- 1635** Finger ischaemia, enlarged spleen and lung nodules

X Puéchal, L Delaval, P Blanche

Letters

- 1637** Low avidity observed for anti-citrullinated peptide antibody is not a general phenomenon for autoantibodies

H Yamada, A Haraguchi, T Tsuru, M Kondo, F Sagawa, H Niuro, Y Nakashima

- 1638** Anti-cyclic citrullinated peptide antibody and pain sensitisation in patients with rheumatoid arthritis: a cross-sectional analysis

Y Y Qiu, T Neogi, L N Muhammad, J Song, M B Bolster, W Marder, A C Heisler, A Wohlfahrt, D Dunlop, Y C Lee

EULAR news

- 1642** News from EULAR

EULAR Communications

Electronic pages

- e228** Correspondence on "Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry" by Machado *et al*

R Bourguiba, M Delplanque, L Savey, V Hentgen, G Grateau, S Georgin-lavialle, French national reference Center for autoinflammatory diseases and AA amyloidosis (CEREMAIA)

- e229** Correspondence on "Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial" by Molto *et al*

U Kiltz, J Braun

- e230** Correspondence on 'The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease' by Wallace *et al*

G K Yardımcı, B E S Yıldırım, B Farisoğulları, L Kilic, O Karadag

- e231** Correspondence on 'NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus' by Linge *et al*

G N Goulielmos, M I Zervou, E Eliopoulos